Latest Global Partnerships News

Way2VAT has secured binding commitments for a A$2.109 million placement, giving the fintech capital to fund the next RBC acquisition payment and its e-invoicing expansion. The raise comes at a 29% discount and carries potential further dilution through free-attaching options.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.

Vmoto Limited posted its strongest half-year sales ever with $35.7 million revenue and a 140% surge in unit sales, underpinned by new global partnerships and international market growth.

Shine Justice Ltd reported a modest 2.3% revenue increase to $209.2 million for FY26, alongside a striking 1,578% jump in net profit after tax to $9.6 million. The company declared a fully franked final dividend of 2.5 cents per share, signalling confidence amid ongoing investments in technology and international expansion.

HighCom Limited’s FY26 results reveal a sharp revenue drop and widening loss driven by a US Government shutdown, but a strengthened leadership team and expanded global sales pipeline set the stage for recovery.

Corporate Travel Management (ASX:CTD) has locked in a five-year global partnership with Amadeus IT Group, aiming to accelerate its digital transformation and operational efficiency across multiple regions.

Wellnex Life has agreed to sell its Pain Away brand to Mentholatum Australasia for up to A$21.3 million, aiming to wipe out debt and sharpen its strategic focus.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.

Arafura Rare Earths has committed to constructing the Nolans Rare Earths Project, Australia's first fully integrated ore-to-oxide operation, backed by binding offtake deals and sovereign financing. Construction is slated to start in September 2026, positioning Nolans as a strategic node in global rare earth supply chains.